PDCD1 and non-small cell lung carcinoma: Compared with immune checkpoint inhibitors that directly block PD-1/PD-L1 interactions, mesoporous silicon nanoparticles (ZnPP@MSN-RGDyK) designed by Zhou et al. showed excellent inhibition of the occurrence and progression of NSCLC-SM through the synergistic immunotherapeutic effects of integrin β3 (β3-int)-specific inhibitor (RGDyK) and Zinc protoporphyrin (ZnPP) [107].